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A 60-year-old woman with end stage liver cirrhosis caused by 
genotype 2 hepatitis C virus (HCV) infection received an or-
thotopic liver transplantation (OLT). The patient was negative 
for the hepatitis B surface antigen (HBsAg) and positive for 
the anti-hepatitis B surface antibody (anti-HBs) prior to and 
one and a half months following the OLT. Due to reactivation 
of hepatitis C, treatment with interferon-alpha and Ribavi-
rin started two months following the OLT and resulted in a 
sustained virological response. We performed a liver biopsy 
because a biochemical response was not achieved. Surpris-
ingly, liver pathology showed HBsAg-positive hepatocytes with 
a lobular hepatitis feature, which had been negative in the 
liver biopsy specimen obtained one and a half months post-
OLT. High titers of both HBsAg and HBeAg were detected, 
while anti-HBs antibodies were not found. Tests for IgM anti-
hepatitis B core antibody and anti-delta virus antibodies were 
negative. The serum HBV DNA titer was over 1×10
7 copies/
mL. A sequencing analysis showed no mutation in the “a” 
determinant region, but revealed a mixture of wild and mu-
tant strains at an overlapping region of the S and P genes (S 
codon 213 (Leu/Ile); P codons 221 (Phe/Tyr) and 222 (Ala/
Thr)). These findings suggest that de novo hepatitis B can 
develop in patients with HCV infection during the post-OLT 
period despite the presence of protective anti-HBs. (Gut Liver 
2011;5:248-252)
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INTRODUCTION
Orthotopic liver transplantation (OLT) remains the only cura-
tive treatment for hepatitis C virus (HCV) induced end-stage 
liver cirrhosis (LC),
1 although post-OLT recurrence of HCV infec-
tion is unavoidable in most of those patients. The recurrence of 
hepatitis C infection and concomitant disease in the liver graft 
may cause substantial morbidity after OLT;
1 however, it is also 
possible that de novo infection of hepatitis B virus (HBV) from 
donor livers, which have had occult HBV infection, may play a 
role in post-OLT hepatitis.
2-4
It has previously been reported that the presence of anti-
hepatitis B surface antibody (anti-HBs) before OLT effectively 
prevents de novo HBV infection from an anti-hepatitis B core 
antibody (anti-HBc) positive donor.
5 However, another report 
has suggested that, despite the presence of a high titer of anti-
HBs, de novo HBV infection from an anti-HBc positive donor 
could occur long after OLT, caused by a variant with an escape 
mutation in the “a” determinant region of the S gene.
6
Recently, we experienced a de novo infection by an HBV 
strain without a mutation in the “a” determinant in a case with 
a protective level of anti-HBs in the serum before and until one 
and half months after OLT; the infection occurred during the 
administration of interferon-alpha for the treatment of recurrent 
hepatitis C. There was a mixture of wild and mutant strains at 
overlapping regions of the S and P genes, resulting in changes 
in the respective frame, S codon 213 (Leu/Ile) vs. P codons 221 
(Phe/Tyr) and 222 (Ala/Thr). Herein we describe the clinical 
course and virological data of the patient. 
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CASE REPORT
A 60-year-old Korean woman underwent OLT for end-stage 
liver cirrhosis caused by chronic hepatitis C. Spontaneously 
acquired anti-HBs was detectable and at protective titer levels 
before and until one and half months after OLT. HCV RNA was 
not detected in serum 3 weeks post OLT. Liver biopsy was per-
formed at one and half months after OLT because the patient’s 
serum aspartate aminotransferase (AST)/alanine aminotransfer-
ase (ALT) were elevated to 192/332 IU/L. 
The first histopathologic finding did not show any evidence 
of acute rejection but was compatible with viral hepatitis (Fig. 1). 
HCV RNA became detectable in the serum at titers of 1.48×10
5 
copies/mL (Roche Amplicor
TM; Roche Diagnostics, Branchburg, 
NJ, USA). The HCV genotype 2 (single) was identified using the 
restriction fragment mass polymorphism (RFMP) method.
7 Its 
exact subtype, however, could not be determined because of 
sequence variation in the subtype-determinant region.
A combination treatment of interferon-alpha 2b (IntronA
TM; 
Schering-Plough Pharmaceuticals, Kenilworth, NJ, USA), 3 mil-
lion units (MU) three times a week, and ribavirin, 600 mg per 
day, was started 2 months post-OLT. Soon after, however, riba-
virin was withdrawn because the patient developed anemia. The 
time interval and dose of interferon-alpha were also adjusted to 
the patient’s degree of leukopenia, and the duration of adminis-
tration was prolonged to one year.
In spite of suboptimal adherence to antiviral therapy, HCV 
RNA was not detectable in the serum at one month post-
treatment. Interferon-alpha injections continued for 4 months 
and were then stopped due to bile peritonitis, which developed 
6 months post-OLT.
Though the serum aminotransferase level was normal dur-
ing interferon treatment, HCV RNA was again detected in titers 
of 9.73×10
2 copies/mL, and the patient’s AST/ALT increased to 
around 80 IU/mL. Both virological and biochemical responses 
occurred 4 months after re-treatment and persisted for 3 
months. While the virological response was sustained, the se-
rum AST/ALT re-elevated to over 60 IU/mL 8 months after re-
treatment.
A liver biopsy was again performed thirteen months after the 
first liver biopsy. The second set of histopathological findings 
revealed features of lobular hepatitis with confluent necrosis 
Fig. 1. Mild periportal lymphocytic 
inflammation with centrilobular, 
spotty hepatocyte necrosis is seen (A, 
H&E stain, ×100). Note the frequent 
intra-acinar apoptotic bodies and 
focal hepatocyte necrosis (B, H&E 
stain, ×400).
Fig. 2. Pronounced centrilobular hepatocyte damage: centrilobular confluent necrosis (A, H&E stain, ×200). Note that some hepatocytes show 
positive cytoplasmic staining with Victoria blue solution, suggesting the presence of hepatitis B surface antigens (HBsAg) (B, Victoria blue stain, 
×400). Immunohistochemical stain for HBsAg shows patchy cytoplasmic staining in the liver biopsy specimen obtained 14 months post-LT (C, 
Envision method, ×200). Comparison with negative immunohistochemical staining of the liver biopsy specimen obtained 2 months post-LT (D, 
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and Victoria blue staining, which strongly suggested HBsAg-
positive hepatocytes (Fig. 2A and B); these findings were con-
firmed by immunohistochemical staining (Fig. 2C). However, 
such results were not seen in the first liver biopsy specimen 
obtained one and a half months after OLT (Fig. 2D).
Serological tests showed high titers of HBsAg (430 IU/mL, 
AxSYM; Abbott Laboratories, Abbott Park, IL, USA) and HBeAg 
(247 IU/mL, AxSYM), but the serum became negative for anti-
HBs. IgM-anti-HBc and anti-delta antibody were negative. As 
measured by real-time PCR, HBV DNA was detectable in titers 
of 9.43×10
7 copies/mL. However, HBV DNA was undetectable 
in serum and a paraffin-embedded liver specimen collected one 
and a half months after OLT. 
As determined by an automated sequencing method (Table 1), 
there were no mutations identified in the “a” determinant region 
of the S gene and precore/core promoter region. A mixture of 
wild and mutant in the overlapping frame region of the S and P 
genes was found instead as follows: S codon 213 (Leu and Ile), 
which can be interpreted as P codons 221 (Phe and Tyr) and 
222 (Ala and Thr) (Fig. 3).
The patient was started on clevudin (Levovir
TM; Bukwang 
Pharmaceutical, Seoul, Korea), 30 mg per day, soon after with-
drawal of interferon-alpha. At the same time, coincidentally, 
gastric cancer with stage III ulcerative type was found in the pa-
tient’s antrum by gastrofiberscopy 13 months post-OLT. For the 
treatment of gastric cancer, we performed surgical resection and 
Table 1. Automated Sequencing for S and P Genes of Hepatitis B Vi-
rus (HBV) DNA
Mutation in S ORF HBV DNA sample
sS171
sI195M
sP120T
sT123N
sK141N
sG145R
sV177A
sV180A
sW182Stop
sA204
sL213I
Ser (TCC):Ser (TCT)=1:2
Ile (ATA)
Pro (CCA)
Thr (ACC)
Lys (AAA)
Gly (GGA)
Val (GTG):Ala (GCG)=3:2
Val (GCT):Val(GTT)=1:5
Trp (TGG)
Ser (AGT)
Leu (TTA):Ile (ATG)=1:2
Fig. 3. No mutations were identified 
in the “a” determinant region of the 
S gene. A mixture of wild and mu-
tant sequences in overlapping frame 
regions of the S and P genes was ob-
served as follows: S codon 213 (Leu 
and Ile), which can be interpreted as 
P codons 221 (Phe and Tyr) and 222 
(Ala and Thr).
*sW182 stop mutation.
Fig. 4. Summary of the clinical course of the patient. Red and blue 
lines indicate alanine and aspartate aminotransferases (ALT and AST), 
respectively. 
anti-HBs, antibody to HBsAg; HCV, hepatitis C virus; HBsAg, hepa-
titis B surface antigen; HBV, hepatitis B virus; IFN-alpha, interferon-
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six cycles of adjuvant chemotherapy. Three months after clevu-
din treatment, HBeAg was still detected, but aminotransferase 
levels became normal. Fig. 4 shows a summary of the clinical 
course of the patient.
DISCUSSION
This case report suggests that, despite the presence of pro-
tective anti-HBs, de novo hepatitis B can develop in patients 
with recurrent hepatitis C during the post-OLT period. In this 
case, two possibilities are suspected regarding the source of 
superinfection by HBV; one is that the patient was infected by 
endogenous serum marker negative (silent) HBV, which was 
suppressed by anti-HBs; the other is that reactivation of HBV 
from the donor occurred, and the patient was silently infected 
without HBV serum markers. Both sources are so-called “occult 
HBV infection.”
Occult HBV infection is defined as the detection of HBV DNA 
without HBsAg with or without the presence of HBV antibod-
ies outside the acute phase window period.
8 Infrequently, occult 
HBV may infect a patient with anti-HBs who has recovered 
from chronic active hepatitis, but whose HBsAg cannot be 
detected by usual assays for persistent, low viral replication, es-
cape mutants.
8
Reportedly, de novo HBV infection after OLT may occur 
in 3.5% of HBsAg-negative recipients, and it originates from 
donors or recipients who are anti-HBc alone or both anti-HBs 
and anti-HBc positive.
2 The use of anti-HBc-positive liver grafts 
makes OLT patients 2.5 times more likely to develop HBV recur-
rence.
9 Therefore, recipients or donors with anti-HBc alone or 
who are both anti-HBs and anti-HBc positive should be care-
fully monitored for de novo HBV infection.
It is unclear how occult HBV infection is reactivated after 
OLT. Generally, there are two hypotheses, immune suppression 
and genomic mutations. As an example of the former theory, 
immunosuppressive chemotherapy can reactivate silent HBV 
infections in patients with hematological malignancies.
10 The S-
escape mutation clearly suggests the latter theory. In one case, 
de novo infection by an HBV variant with mutations in the “a” 
determinant of the S gene, Met 133 Thr (codon change ATG 
to ACG) and Asn 131 Thr, developed 2 years post-OLT, even 
though the patient had vaccine-induced anti-HBs (serum titer 
256 IU/L) 1 year post-OLT.
6
Another possibility is that HCV might promote the replication 
of HBV in the liver, which is frequently co-infected with the 
silent HBV mutant.
11 In this case, recurrent hepatitis C was fol-
lowed by de novo hepatitis B. It also developed despite the pres-
ence of protective anti-HBs, but there was no mutation in the “a” 
determinant region of the S gene. Therefore, it is conceivable 
in this case that pre-activated HCV replication might have pro-
moted the reactivation of silently infected HBV in a donor liver 
a short period after OLT. 
A mixture of wild and mutant strains at overlapping reading 
frames of the S and P genes (S codon 213 (Leu/Ile), P codons 
221 (Phe/Tyr) and 222 (Ala/Thr)) was detected, as shown in Fig. 3. 
The mutations in either the S or P gene can produce function-
ally significant changes in the respective overlapping gene, re-
sulting in changed antigenicity and/or replication, but the viro-
logical and clinical significance of such overlapping mutations 
is unclear.
12 In this case, because HBeAg was detected and HBV 
DNA was still high 3 months after administration of clevudin, it 
should be clarified that the mutations in the overlapping frame 
gene regions, S codon L213I (P codons P221T and A222T), may 
be associated with escape mutation as well as drug resistance. 
An interesting point of this case concerns the sustained HCV 
suppression, which occurred even with insufficient treatment 
of interferon-alpha. It can be partly explained by a theory that 
HBV superinfection in chronic HCV carriers has a severe clinical 
course and strongly and persistently depresses HCV.
13 There are 
two hypotheses to explain the mechanism of profound suppres-
sion of chronic hepatitis C after superinfection with HBV: an 
anti-virus specific immune response induced by HBV infection
14 
and an innocent bystander mechanism induced by an HBV spe-
cific T cell response.
15
In conclusion, this case report proves that post-OLT de novo 
infection of HBV without the “a” determinant mutation can de-
velop even in patients with protective anti-HBs. In addition, de 
novo hepatitis B and recurrent hepatitis C should both be con-
sidered as etiologic factors of post-OLT hepatitis in patients with 
HCV infection.
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